Details for New Drug Application (NDA): 209483
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
NDA 209483 describes IMPOYZ, which is a drug marketed by Primus Pharms and is included in one NDA. There are four patents protecting this drug. Additional details are available on the IMPOYZ profile page.
The generic ingredient in IMPOYZ is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
The generic ingredient in IMPOYZ is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
Summary for 209483
| Tradename: | IMPOYZ |
| Applicant: | Primus Pharms |
| Ingredient: | clobetasol propionate |
| Patents: | 4 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 209483
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CREAM;TOPICAL | Strength | 0.025% | ||||
| Approval Date: | Nov 28, 2017 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Try a Trial | Patent Expiration: | Aug 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | PSORIASIS | ||||||||
| Patent: | ⤷ Try a Trial | Patent Expiration: | Aug 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF MODERATE PLAQUE PSORIASIS | ||||||||
| Patent: | ⤷ Try a Trial | Patent Expiration: | Aug 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF PLAQUE PSORIASIS | ||||||||
Complete Access Available with Subscription
